In vitro and in vivo activities of HQQ-3, a new triazole antifungal agent

4Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

The activity of HQQ-3, a new triazole antifungal agent, was evaluated and compared with those of fluconazole, ketoconazole and terbinafine in vitro and with fluconazole in vivo. HQQ-3 exhibited potent in vitro activity against clinically important fungi. The activity of HQQ-3 against Candida spp. was superior to those of fluconazole and terbinafine and comparable or superior to that of ketoconazole. HQQ-3 retained potent activity against Candida albicans strains with low levels of susceptibility to fluconazole (fluconazole MIC 80s range, 4 to >64 μg/ml). Against Cryptococcus neoformans and filamentous fungi, the activity of HQQ-3 was superior to that of fluconazole. HQQ-3 also exhibited potent in vivo activity against murine systemic infections caused by C. albicns and C. krusei. The 50% effective doses against these infections were 0.12 to 1.9 mg/kg of body weight. These result suggest that HQQ-3 may be useful in the treatment of candidiasis. © 2006 Pharmaceutical Society of Japan.

Author supplied keywords

Cite

CITATION STYLE

APA

Zhao, J. X., Cao, Y. Y., Quan, H., Liu, C. M., He, Q. Q., Wu, Q. Y., … Jiang, Y. Y. (2006). In vitro and in vivo activities of HQQ-3, a new triazole antifungal agent. Biological and Pharmaceutical Bulletin, 29(10), 2031–2034. https://doi.org/10.1248/bpb.29.2031

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free